MOLECULAR CANCER THERAPEUTICS

AN OFFICIAL JOURNAL OF THE American Association for Cancer Research

Publishing Information

AAACR Officers
Antoni Ribas, President
David A. Tuveson, President-Elect
Elaine R. Mardis, Past President
William N. Hait, Treasurer
Margaret Foti, Chief Executive Officer

Publications Committee
Victor E. Velculescu, Chairperson
Adriano Albini
Laura Fejerman
Masanori Hatakeyama
Catriona H.M. Jamieson
Jos Jonkers
Virginia G. Kiklamani
Andrew Kung
Jonathan D. Licht
Ira Mellman
Gordon B. Mills
Kunle Odunsi
Kenneth J. Pienta
Joshua D. Rabinowitz
David L. Rimm
Mack Roach, III
Sheila K. Singh
Sheila A. Stewart
Miguel A. Villalona-Calero
Joshua D. Rabinowitz
Ira Mellman
Gordon B. Mills
Kunle Odunsi
Kenneth J. Pienta
Joshua D. Rabinowitz

Molecular Cancer Therapeutics strives to be the top choice for publishing the best science in the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanisms of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms. While the Journal’s main focus is on small molecule and protein drugs, other molecular entities may be considered.

Molecular Cancer Therapeutics is abstracted and/or indexed in Current Contents/Clinical Medicine, MEDLINE, Science Citation Index, Scopus, and Web of Science.

Submission of Manuscripts
Online manuscript submission is welcomed at https://mct.msubmit.net. Before submitting a manuscript, please read the Instructions for Authors, which is available from the Journal’s home page at https://mct.aacrjournals.org.

Publication Charges
Articles will be published with the understanding that the author(s) will pay both a publication fee plus a color figure handling fee. Please see the Publication Fees and Reprints page which is available at https://aacrjournals.org/content/authors/publication-fees-and-reprints.

Subscription Information
Nonmember Individuals
Subscriptions include online access only. Contacts listed below are for nonmember individual subscriptions.

USA and Rest of World (excluding Japan)
American Association for Cancer Research, 615 Chestnut Street, Philadelphia, PA 19106; 1-855-744-4667; pubsales@aacr.org

Japan
e-support@maruzen.co.jp;
journal@kinokuniya.co.jp; usaco@usaco.co.jp

International print subscriptions include cost of surface mail. Expedited mailing is available. Contact the American Association for Cancer Research for rates.

Site Licenses
For information about institutional site licenses, contact pubsales@aacr.org.

AACR Members
AACR members may opt to receive either a print subscription with online access to content or an online-only subscription. Contact membership@aacr.org or visit the membership page at https://aacr.org for more information.

Single Issue Sales/Claims
Due to the impact of COVID-19, the AACR has discontinued single issue orders and fulfillment of claims through December 31, 2021.

Advertising Information
For information about advertising in AACR journals, contact The Walchli Tauber Group, Inc., 2225 Old Emmorton Road, Suite 201, Bel Air, MD 21205; (443) 512-8899; maura.paoletti@wt-group.com.

Copyright and Permissions
Content printed in or disseminated by Molecular Cancer Therapeutics is protected by copyright. Authors who wish to publish material in Molecular Cancer Therapeutics must formally transfer copyright to the AACR. All authors must sign copyright transfer forms before the AACR can proceed with publication.

To read the complete AACR Copyright and Permissions Policy, visit https://aacrjournals.org/content/authors/copyrightPermissions-and-access.